Insights
Search Results
Client Highlights
4.17.26
Firm Advises Neurona Therapeutics on Acquisition by UCB
On April 17, 2026, UCB, a global biopharmaceutical company, announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system. Under the terms of the agreement, UCB will pay $650 million upfront and up to $500 million in potential future milestone payments, subject to certain closing conditions. Wilson Sonsini Goodrich & Rosati advised Neurona on the transaction.
Client Highlights
3.27.26
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Client Highlights
2.05.26
Wilson Sonsini Advises SpyGlass Pharma on $150 Million IPO
On February 5, 2026, SpyGlass Pharma, Inc., a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by SpyGlass Pharma, are expected to be approximately $150 million. Wilson Sonsini Goodrich & Rosati advised SpyGlass Pharma on the transaction.
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
Client Highlights
1.08.26
Firm Advises InduPro on Strategic Investment, Research Collaboration with Sanofi
On December 10, 2025, InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, announced a strategic equity investment and research collaboration with Sanofi. Wilson Sonsini Goodrich & Rosati advised InduPro on the transaction.
Client Highlights
1.08.26
Wilson Sonsini Advises InduPro on $950 Million Strategic Collaboration with Eli Lilly
On January 7, 2026, InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, announced a global strategic collaboration and licensing agreement, and equity investment, with Eli Lilly and Company to discover novel oncology treatments using InduPro’s proximity-guided platform. Under the terms of the agreement, InduPro and Eli Lilly will collaborate on up to three targets, for a total deal value of up to approximately $950 million. Wilson Sonsini Goodrich & Rosati advised InduPro on the transaction.
Client Highlights
10.15.25
Firm Advises Sofinnova, Novo Holdings, and Forbion on Expedition Therapeutics’ $165 Million Series A Financing
On October 9, 2025, Expedition Therapeutics, a biotech company developing therapies for novel inflammatory and respiratory diseases, announced the closing of an oversubscribed $165 million Series A financing. The round was co-led by Sofinnova Investments and Novo Holdings, with additional investment from Forbion, Dawn Biopharma, Adage, Balyasny, Logos Capital, Sanofi Ventures, and existing investors BVF Partners and Venrock Healthcare Capital Partners. Wilson Sonsini Goodrich & Rosati advised co-lead investors Sofinnova and Novo Holdings, as well as syndicate investor Forbion, on the transaction.
Client Highlights
6.17.25
Wilson Sonsini Advises Verve Therapeutics on IP Matters Related to Merger with Lilly
On June 17, 2025, Eli Lilly and Company and Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, announced a definitive agreement for Lilly to acquire Verve. Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on IP matters related to the transaction.
Client Highlights
3.04.25
Wilson Sonsini Advises Investors on Callio Therapeutics' $187 Million Series A
On March 3, 2025, Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, announced its launch with the closing of a $187 million Series A financing. Frazier Life Sciences led the round with significant participation from Jeito Capital alongside other life sciences investors, including Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital, and EDBI. Wilson Sonsini advised Novo Holdings, Platanus, and Pureos Bioventures on the transaction.
Client Highlights
10.24.23
Firm Advises Assembly Biosciences on Partnership with Gilead Sciences
On October 17, 2023, Gilead Sciences and Assembly Biosciences, a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, announced that they have entered into a 12-year partnership to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio’s established areas of herpesviruses, hepatitis B virus (HBV), and hepatitis D virus (HDV). Wilson Sonsini Goodrich & Rosati advised Assembly Bio on the transaction.
Assembly Bio’s current portfolio of small molecule antiviral therapeutics includes both clinical and preclinical programs, including next-generation core inhibitor ABI-4334 for the treatment of HBV, long-acting helicase-primase inhibitor ABI-5366 for herpes simplex virus (HSV), an orally bioavailable HDV entry inhibitor ABI-6250, and a pan-herpes polymerase inhibitor program.
Assembly Bio’s current portfolio of small molecule antiviral therapeutics includes both clinical and preclinical programs, including next-generation core inhibitor ABI-4334 for the treatment of HBV, long-acting helicase-primase inhibitor ABI-5366 for herpes simplex virus (HSV), an orally bioavailable HDV entry inhibitor ABI-6250, and a pan-herpes polymerase inhibitor program.
Client Highlights
7.01.22
Wilson Sonsini Advises Kedalion Therapeutics on Acquisition by Novartis
On June 30, 2022, Novartis announced that it acquired Kedalion Therapeutics and its AcuStream technology, an innovative device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. Wilson Sonsini Goodrich & Rosati advised Kedalion on the transaction.
Kedalion is a clinical-stage, venture-funded ophthalmic drug company based in Menlo Park, California. In November 2021, Kedalion Therapeutics announced the completion of its Series B financing led by Novartis, which included an exclusive option to acquire the company and its AcuStream technology.
Kedalion is a clinical-stage, venture-funded ophthalmic drug company based in Menlo Park, California. In November 2021, Kedalion Therapeutics announced the completion of its Series B financing led by Novartis, which included an exclusive option to acquire the company and its AcuStream technology.
Client Highlights
11.17.21
Wilson Sonsini Advises Kedalion on Series B Funding, Signing of Option to Acquire Agreement
On November 15, 2021, Kedalion Therapeutics announced the completion of its Series B financing led by Novartis and involving a combination of new and existing investors. The Novartis investment includes an exclusive option to acquire the company and its AcuStream technology. The agreement follows a feasibility study agreement with the AcuStream technology signed earlier this year. The subsequent feasibility study has been completed with successful results. Collaboration between the two parties is ongoing. The financial and other terms of this transaction have not been disclosed.
Client Advisories
11.15.21
Wilson Sonsini Advises Combangio in Its Acquisition by Kala Pharmaceuticals
On November 15, 2021, Kala Pharmaceuticals, a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye, announced that it has acquired Combangio, a private, clinical-stage company developing regenerative biotherapies for severe ocular surface diseases. Combangio is developing CMB-012, a novel investigational secretome therapy, now known as KPI-012, to address the complex wound healing process in persistent corneal epithelial defect (PCED) and other severe ocular diseases driven by impaired corneal healing. Wilson Sonsini Goodrich & Rosati represented Combangio in the transaction.